J B Chemicals & Pharmaceuticals Ltd
J.B. Chemicals and Pharmaceuticals Limited, established in 1976, is one of India's leading pharmaceutical companies. An integrated, publicly-listed organization with a focus on supplying affordable, quality products both in India and internationally, JBCPL is trusted by healthcare professionals globally. [1]
- Market Cap ₹ 26,435 Cr.
- Current Price ₹ 1,702
- High / Low ₹ 2,030 / 1,371
- Stock P/E 44.0
- Book Value ₹ 203
- Dividend Yield 0.72 %
- ROCE 24.5 %
- ROE 20.0 %
- Face Value ₹ 1.00
Pros
- Company has reduced debt.
- Company is almost debt free.
- Company has been maintaining a healthy dividend payout of 35.2%
Cons
- Stock is trading at 8.37 times its book value
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln
Part of BSE Healthcare BSE 250 SmallCap Index Nifty Smallcap 250 BSE Allcap BSE SmallCap Select Index
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
816 | 957 | 1,061 | 1,144 | 1,175 | 1,250 | 1,501 | 1,641 | 1,892 | 2,190 | 2,884 | 3,299 | 3,517 | |
705 | 802 | 868 | 917 | 952 | 1,050 | 1,209 | 1,270 | 1,340 | 1,681 | 2,219 | 2,419 | 2,566 | |
Operating Profit | 111 | 154 | 193 | 226 | 222 | 199 | 292 | 370 | 552 | 509 | 665 | 880 | 951 |
OPM % | 14% | 16% | 18% | 20% | 19% | 16% | 19% | 23% | 29% | 23% | 23% | 27% | 27% |
26 | -27 | 10 | 55 | 46 | 39 | 37 | 37 | 116 | 39 | 9 | 34 | 37 | |
Interest | 5 | 6 | 7 | 10 | 5 | 3 | 5 | 3 | 7 | 5 | 34 | 41 | 26 |
Depreciation | 24 | 27 | 38 | 40 | 46 | 56 | 55 | 65 | 67 | 71 | 112 | 135 | 154 |
Profit before tax | 108 | 94 | 159 | 231 | 217 | 179 | 269 | 340 | 594 | 471 | 527 | 738 | 808 |
Tax % | 21% | 27% | 29% | 22% | 20% | 29% | 32% | 21% | 25% | 23% | 26% | 26% | |
85 | 68 | 114 | 179 | 173 | 128 | 182 | 268 | 447 | 361 | 389 | 543 | 600 | |
EPS in Rs | 5.01 | 4.04 | 6.70 | 10.57 | 10.20 | 7.66 | 11.34 | 17.34 | 28.92 | 23.35 | 25.12 | 35.01 | 38.67 |
Dividend Payout % | 30% | 37% | 105% | 24% | 5% | 13% | 22% | 32% | 29% | 35% | 35% | 35% |
Compounded Sales Growth | |
---|---|
10 Years: | 13% |
5 Years: | 17% |
3 Years: | 20% |
TTM: | 13% |
Compounded Profit Growth | |
---|---|
10 Years: | 19% |
5 Years: | 26% |
3 Years: | 10% |
TTM: | 25% |
Stock Price CAGR | |
---|---|
10 Years: | 33% |
5 Years: | 54% |
3 Years: | 29% |
1 Year: | 18% |
Return on Equity | |
---|---|
10 Years: | 16% |
5 Years: | 19% |
3 Years: | 18% |
Last Year: | 20% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Sep 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 17 | 17 | 17 | 17 | 17 | 17 | 16 | 15 | 15 | 15 | 15 | 16 | 16 |
Reserves | 992 | 1,031 | 999 | 1,206 | 1,371 | 1,437 | 1,469 | 1,430 | 1,791 | 2,088 | 2,427 | 2,871 | 3,142 |
50 | 93 | 105 | 175 | 49 | 28 | 26 | 29 | 39 | 52 | 547 | 359 | 90 | |
214 | 201 | 327 | 244 | 248 | 285 | 283 | 337 | 355 | 382 | 480 | 668 | 699 | |
Total Liabilities | 1,273 | 1,342 | 1,449 | 1,641 | 1,684 | 1,767 | 1,793 | 1,811 | 2,200 | 2,538 | 3,470 | 3,914 | 3,946 |
294 | 282 | 301 | 369 | 609 | 570 | 552 | 583 | 565 | 1,204 | 1,822 | 1,925 | 1,934 | |
CWIP | 5 | 46 | 55 | 135 | 4 | 17 | 15 | 16 | 26 | 19 | 55 | 76 | 42 |
Investments | 434 | 536 | 598 | 612 | 544 | 567 | 589 | 536 | 811 | 146 | 339 | 531 | 488 |
540 | 477 | 495 | 525 | 528 | 613 | 636 | 676 | 799 | 1,170 | 1,254 | 1,381 | 1,482 | |
Total Assets | 1,273 | 1,342 | 1,449 | 1,641 | 1,684 | 1,767 | 1,793 | 1,811 | 2,200 | 2,538 | 3,470 | 3,914 | 3,946 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
80 | -12 | 143 | 171 | 178 | 116 | 193 | 272 | 335 | 147 | 629 | 789 | |
-112 | -139 | -122 | -52 | -42 | -24 | -28 | 24 | -231 | 4 | -956 | -412 | |
-31 | 12 | -23 | -97 | -165 | -59 | -156 | -305 | -87 | -138 | 343 | -374 | |
Net Cash Flow | -62 | -138 | -2 | 22 | -30 | 32 | 9 | -10 | 18 | 13 | 16 | 2 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 87 | 95 | 85 | 85 | 82 | 88 | 73 | 77 | 72 | 86 | 66 | 69 |
Inventory Days | 97 | 108 | 109 | 108 | 131 | 134 | 142 | 149 | 163 | 172 | 136 | 152 |
Days Payable | 56 | 50 | 53 | 56 | 65 | 76 | 76 | 97 | 96 | 96 | 78 | 109 |
Cash Conversion Cycle | 128 | 152 | 141 | 137 | 149 | 145 | 139 | 128 | 139 | 162 | 124 | 112 |
Working Capital Days | 84 | 105 | 60 | 94 | 95 | 107 | 98 | 88 | 95 | 130 | 100 | 88 |
ROCE % | 9% | 13% | 14% | 17% | 12% | 9% | 17% | 22% | 32% | 22% | 22% | 24% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS
1d - Allotment of 95,300 equity shares under ESOP.
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
12 Nov - Transcript of Q2 FY25 earnings call for JB Pharma.
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
7 Nov - Audio recording of Q2 results investor call available.
- Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate 7 Nov
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
7 Nov - Newspaper cutting of extract of consolidated financial results for quarter ended on September 30, 2024
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2012
from nse
-
Financial Year 2011
from bse
Concalls
-
Nov 2024Transcript PPT
-
Aug 2024Transcript PPT
-
May 2024Transcript PPT
-
Feb 2024Transcript PPT REC
-
Dec 2023Transcript PPT
-
Nov 2023Transcript PPT
-
Aug 2023Transcript PPT
-
May 2023Transcript PPT
-
Feb 2023Transcript PPT
-
Jan 2023TranscriptNotesPPT
-
Nov 2022Transcript PPT
-
Aug 2022Transcript PPT
-
May 2022Transcript PPT
-
Feb 2022Transcript PPT
-
Jan 2022Transcript PPT
-
Nov 2021Transcript PPT
-
Aug 2021Transcript PPT
-
Aug 2021TranscriptPPT
-
Jun 2021TranscriptPPT
-
Mar 2021TranscriptNotesPPT
-
Feb 2021TranscriptNotesPPT
-
Nov 2020TranscriptNotesPPT
-
Jun 2020TranscriptNotesPPT
-
Feb 2020TranscriptNotesPPT
-
Sep 2019TranscriptNotesPPT
Revenue Split H1FY24
Domestic Formulations - 55%
Export Formulations - 30%
Contract Manufacturing - 13%
APIs - 2% [1]